<DOC>
	<DOCNO>NCT01403948</DOCNO>
	<brief_summary>The purpose investigate maximum tolerate dose ( MTD ) , safety tolerability , pharmacokinetics efficacy BI 836826 monotherapy patient relapse refractory non-Hodgkin lymphoma least prior treatment .</brief_summary>
	<brief_title>BI 836826 Dose Escalation Patients With Relapsed Refractory Non-Hodgkin Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients relapse refractory nonHodgkin lymphoma B cell origin ( mature B cell lymphoma accord WHO ) consider candidate intensive antilymphoma therapy 2 . Patients must either aggressive NHL receive least one prior antiCD20 contain immunochemotherapy indolent NHL receive antiCD20 therapy least two prior therapy 3 . Measurable disease compute tomography ( CT ) scan involvement one clearly demarcate lesion =2 cm two clearly demarcated lesion &gt; 1.5 cm long diameter ( criterion apply expansion cohort ) 4 . Relapse progression disease indication therapy per investigator ` judgement 5 . Life expectancy =3 month 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Exclusion criterion : 1 . Primary central nervous system ( CNS ) lymphoma know CNS involvement 2 . Prior history malignancy mature B cell neoplasm accord WHO classification ( except basal cell squamous cell carcinoma skin , carcinoma situ uterine cervix breast treat curative therapy ) unless subject free disease without treatment least 5 year 3 . Last chemotherapy &lt; 4 week prior visit 1 4 . Last antiCD20 therapy ( nonradiolabelled ) &lt; 4 week prior visit 1 5 . Last corticosteroid &lt; 2 week prior visit 1 unless dose less equal 10 mg/day prednisolone equivalent 6 . Highdose therapy stem cell support &lt; 6 month prior visit 1 7 . Radioimmunotherapy &lt; 3 month prior visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>